Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride.
Radium-223
metastatic prostate cancer
neutrophil to lymphocyte ratio
prognostic factor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Sep 2022
22 Sep 2022
Historique:
received:
24
08
2022
revised:
14
09
2022
accepted:
20
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
The neutrophil to lymphocyte ratio (NLR) at baseline has been shown to have prognostic value in metastatic prostate cancer. Little is known about the importance of a change in the NLR during treatment in patients treated with Radium-223 (223Ra). We investigated the prognostic value of the NLR at baseline and during therapy in patients with metastatic prostate cancer treated with 223Ra and also in patients treated with Docetaxel. We reviewed all patients treated with 223Ra in our center and randomly chosen patients treated with Docetaxel. Patients were stratified according to NLR ≤ 5 and >5 at baseline and at 12 weeks of therapy. The relationship between NLR measured at baseline and at 12 weeks and overall survival (OS) were evaluated. A total of 149 patients treated with 223Ra and 170 with Docetaxel were evaluated. For patients treated with 223Ra, overall survival was significantly better in patients that had both an NLR ≤ 5 at baseline and at 12 weeks. No such effect of NLR was found in patients treated with Docetaxel. In the present study, NLR at baseline and after 12 weeks of therapy was found to be prognostic factor in patients treated with 223Ra but not in those treated with Docetaxel.
Identifiants
pubmed: 36230529
pii: cancers14194606
doi: 10.3390/cancers14194606
pmc: PMC9559675
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
J Immunother Cancer. 2018 Jul 16;6(1):74
pubmed: 30012216
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Medicine (Baltimore). 2021 Oct 1;100(39):e27361
pubmed: 34596147
Acta Oncol. 2021 Jun;60(6):704-713
pubmed: 33586577
J Natl Compr Canc Netw. 2021 Feb 02;19(2):134-143
pubmed: 33545689
Ann Oncol. 2015 Apr;26(4):743-749
pubmed: 25515657
Semin Oncol. 2001 Aug;28(4 Suppl 15):3-7
pubmed: 11685722
Curr Oncol Rep. 2021 Jun 14;23(8):88
pubmed: 34125308
Cancer Immunol Immunother. 2020 Sep;69(9):1813-1822
pubmed: 32350592
Int J Surg. 2018 Dec;60:216-223
pubmed: 30468905
Clin Genitourin Cancer. 2013 Dec;11(4):423-30
pubmed: 23816526
Ann Oncol. 2015 Apr;26(4):750-755
pubmed: 25538172
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):142-151
pubmed: 30227198
Cells. 2021 Jan 25;10(2):
pubmed: 33503958
Clin Cancer Res. 2021 Aug 15;27(16):4549-4556
pubmed: 34187853
ESMO Open. 2021 Oct;6(5):100241
pubmed: 34450475
Int Urol Nephrol. 2014 Aug;46(8):1531-5
pubmed: 24526335
Front Oncol. 2012 Aug 24;2:95
pubmed: 22937524
Eur J Cancer. 2021 Jul;151:211-220
pubmed: 34022698
J Immunother Cancer. 2018 Jan 22;6(1):5
pubmed: 29353553
Radiat Res. 2004 Jul;162(1):1-19
pubmed: 15222781
Acta Oncol. 2017 Apr;56(4):555-562
pubmed: 28068151
Cancers (Basel). 2022 Mar 29;14(7):
pubmed: 35406515
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1063-1074
pubmed: 34486070
BMC Med. 2020 Nov 20;18(1):360
pubmed: 33213430